Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Analysis of Population Pharmacokinetic Data

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...

Bioequivalence Data: Statistical Interpretation

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...

Dosage Regimens: Partial Pharmacokinetic Parameters

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

Measurement of Bioavailability: Pharmacodynamic Methods

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-world analysis and cost-effectiveness of iron chelation therapy adherence in transfusion-dependent thalassemia.

Expert review of hematology·2025

Same author

Real-world treatment patterns and outcomes for patients with CLL using the Australian pharmaceutical benefits scheme (PBS) dataset.

Leukemia & lymphoma·2024

Same author

The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: a systematic review.

Health and quality of life outcomes·2024

Same author

Corrigendum: Drug-related problems among transfusion-dependent thalassemia patients: a real-world evidence study.

Frontiers in pharmacology·2023

Same author

Budget impact of increasing uptake of denosumab for the treatment of postmenopausal osteoporosis in Malaysia.

Archives of osteoporosis·2023

Same author

Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China.

Journal of medical economics·2023

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

How to improve pharmacoeconomic data generalisability between different countries.

Expert Opinion on Pharmacotherapy

|July 31, 2007

Summary

Pharmacoeconomics is crucial for justifying healthcare spending and drug approvals. Achieving consensus on cost-effectiveness data is vital for global acceptance and drug subsidy decisions.

Area of Science:

Health Economics
Pharmaceutical Policy
Outcomes Research

Background:

Escalating global healthcare costs necessitate greater financial accountability.
Decision-makers require cost-effectiveness data for drug formulary inclusion and subsidies.
International disparities in pharmacoeconomic data hinder universal drug approval processes.

Discussion:

Establishing a consensus on universally acceptable pharmacoeconomic data is essential.
Improving the generalizability of pharmacoeconomic evidence across different countries is a key challenge.
Standardized methodologies can enhance the comparability and acceptance of economic evaluations.

Key Insights:

Pharmacoeconomic evaluations are critical for evidence-based healthcare resource allocation.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Related Experiment Videos

Last Updated: Jul 13, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Lack of standardized data hinders international drug policy and market access.

Consensus on data requirements will streamline drug approval and subsidy processes globally.

Outlook:

Future research should focus on developing harmonized pharmacoeconomic guidelines.
International collaboration is needed to foster consistent data generation and interpretation.
Advancements in pharmacoeconomics will support sustainable healthcare systems worldwide.